; (5) describe how the Food and Drug Administration has considered real-world evidence or other data and information, including from use of the biological product in other countries, in determining whether a biosimilar biological product meets the criteria for the interchangeability designation; (6) describe the differences between the regulatory and scientific considerations for determining a biological product to be interchangeable under section 351(k)(4) of such Act ( 42 U.S.C. 262(k)(4) ) and the system for assigning therapeutic equivalence ratings to drugs approved under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ); and (7) assess the uptake of biosimilar biological products, and the impact of the efforts of the Food and Drug Administration to improve adoption of biosimilar biological products through multimedia education and curriculum materials. (b) Stakeholder input For purposes of developing the report described in subsection (a), the Secretary may convene workshops or listening sessions, establish dockets to receive public comment, or use other means to obtain input from interested stakeholders. (c) Information disclosure Nothing in this section shall be construed to authorize the disclosure of information that is prohibited from disclosure under section 301(j) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 331(j) ) or section 1905 of title 18, United States Code, or subject to withholding under paragraph (4) of section 552(b) of title 5, United States Code (commonly referred to as the Freedom of Information Act ).